Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot Study.
J Clin Exp Hepatol
; 12(4): 1083-1090, 2022.
Article
en En
| MEDLINE
| ID: mdl-35814506
ALD, alcoholic liver disease; CLD, chronic liver disease; ED, Erectile dysfunction; FIB-4; FIB-4, fibrosis index based on 4 factors; HRQOL, health-related quality of life; IIEF-5; IIEF-5, the International Index of Erectile Function-5; LC, liver cirrhosis; LSM, liver stiffness measurement; MAP, mean arterial pressure; PDE-5 I; PDE5-I, phosphodiesterase inhibitors; PDEs, phosphodiesterases; PPH, porto-pulmonary hypertension; QOL, quality of life; SMT, standard medical therapy; TAA, thioacetamide; TE, transient elastography; WHOQOL-BREF; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; erectile dysfunction
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Aspecto:
Patient_preference
Idioma:
En
Revista:
J Clin Exp Hepatol
Año:
2022
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
India